Browsing by Author "Dube, Admire"

Now showing 1 - 6 of 6

Chitosan-coated liposomes of Carrisa spinarum extract: synthesis, analysis and anti-pneumococcal potency
(ICE Publishing, 2023-02-16) Rubaka, Clarence; Gathirwa, Jeremiah; Malebo, Hamisi; Swai, Hulda; Sibuyi, Nicole; Hilonga, Askwar; Dube, Admire
In the present study, a chitosan (CS)-coated liposome (LipCsP-Chitosan) nanocarrier was fabricated for the delivery of Carissa spinarum (CsP) polyphenols to improve bioavailability and anti-pneumococcal potential against Klebsiella pneumoniae. LipCsP-Chitosan was synthesized by the ion gelation method and characterized by using a Malvern zetasizer and Fourier Transform Infrared (FTIR); CsP encapsulation and release kinetics were investigated. Anti-pneumococcal activity of the nanoformulations was accessed by agar-well diffusion and microdilution assays. LipCsP-chitosan exhibited a hydrodynamic size and zeta potential of 365.22 ± 0.70 nm and +39.30 ± 0.61 mV, respectively. CsP had an encapsulation efficiency of 81.5%. FTIR analysis revealed the interaction of the liposomes with chitosan and the CsP. A biphasic CsP release profile followed by a sustained release pattern was observed. LiPCsP-Chitosan presented a higher bioaccessibility of polyphenols in the simulated gastric phase (74.1% ± 1.3) than in the simulated intestinal phase (63.32% ± 1.00). LipCsP-chitosan had a relative inhibition zone diameter of 84.33% ± 2.51 when compared to CsP. At minimum inhibition concentration of 31.25 mg/mL, LipCsP-Chitosan reduced the viability of Klebsiella pneumoniae by 57.45% ± 3.76 after 24 h. The results obtained from the current study offer a new approach to the utilization of LipCsP-Chitosan as nanocarriers for candidate anti-pneumococcal agents.
Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes
(Taylor & Francis Group., 2019-04-22) Omarch, Geofrey; Kippie, Yunus; Mentor, Shireen; Ebrahim, Naushaad; Fisher, David; Murilla, Grace; Swai, Hulda; Dube, Admire
Nanoparticles (NPs) have gained importance in addressing drug delivery challenges across biological barriers. Here, we reformulated pentamidine, a drug used to treat Human African Trypanosomiasis (HAT) in polymer based nanoparticles and liposomes and compared their capability to enhance pentamidine penetration across blood brain barrier (BBB). Size, polydispersity index, zeta potential, morphology, pentamidine loading and drug release profiles were determined by various methods. Cytotoxicity was tested against the immortalized mouse brain endothelioma cells over 96 h. Moreover, cells monolayer integrity and transportation ability were examined for 24 h. Pentamidine-loaded polycaprolactone (PCL) nanoparticles had a mean size of 267.58, PDI of 0.25 and zeta potential of –28.1 mV and pentamidine-loaded liposomes had a mean size of 119.61 nm, PDI of 0.25 and zeta potential 11.78. Pentamidine loading was 0.16 mg/mg (w/w) and 0.17 mg/mg (w/w) in PCL NPs and liposomes respectively. PCL nanoparticles and liposomes released 12.13% and 22.21% of pentamidine respectively after 24 h. Liposomes transported 87% of the dose, PCL NPs 66% of the dose and free pentamidine penetration was 63% of the dose. These results suggest that liposomes are comparatively promising nanocarriers for transportation of pentamidine across BBB.
Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities
(Springer, 2015-03-28) Tukulula, Matshawandile; Hayeshi, Rose; Fonteh, Pascaline; Meyer, Debra; Ndamase, Abongile; Madziva, Michael T.; Khumalo, Vincent; Lubuschagne, Philip; Naicker, Brendon; Swai, Hulda; Dube, Admire
Purpose There is significant interest in the application of nanoparticles to deliver immunostimulatory signals to cells.We hypothesized that curdlan (immune stimulating polymer) could be conjugated to PLGA and nanoparticles from this copolymer would possess immunostimulatory activity, be non-cytotoxic and function as an effective sustained drug release system. Methods Carbodiimide chemistry was employed to conjugate curdlan to PLGA. The conjugate (C-PLGA) was characterized using 1H and 13C NMR, FTIR, DSC and TGA. Nanoparticles were synthesized using an emulsion-solvent evaporation technique. Immunostimulatory activity was characterized in THP-1 derived macrophages. MTTassay and real-time impedance measurements were used to characterize polymer and nanoparticle toxicity and uptake in macrophages. Drug delivery capability was assessed across Caco-2 cells using rifampicin as a model drug. Results Spectral characterization confirmed successful synthesis of C-PLGA. C-PLGA nanoparticles enhanced phosphorylated ERK production in macrophages indicating cell stimulation. Nanoparticles provided slow release of rifampicin across Caco-2 cells. Polymers but not nanoparticles altered the adhesion profiles of the macrophages. Impedance measurements suggested Ca2+ dependent uptake of nanoparticles by the macrophages. Conclusions PLGA nanoparticles with macrophage stimulating and sustained drug delivery capabilities have been prepared. These nanoparticles can be used to stimulate macrophages and concurrently deliver drug in infectious disease therapy.
Nanomedicine: Past, present and future - A global perspective.
(Elsevier Inc, 2015-12-18) Chang, Esther; Harford, Joe; Eaton, Michael; Boisseau, Patrick; Dube, Admire; Hayeshi, Rose; Swai, Hulda; Lee, Dong
Nanomedicine is an emerging and rapidly evolving field and includes the use of nanoparticles for diagnosis and therapy of a variety of diseases, as well as in regenerative medicine. In this mini-review, leaders in the field from around the globe provide a personal perspective on the development of nanomedicine. The focus lies on the translation from research to development and the innovation supply chain, as well as the current status of nanomedicine in industry. The role of academic professional societies and the importance of government funding are discussed. Nanomedicine to combat infectious diseases of poverty is highlighted along with other pertinent examples of recent breakthroughs in nanomedicine. Taken together, this review provides a unique and global perspective on the emerging field of nanomedicine.
Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice
(Dovepress, 2015-02-20) Melariri, Paula; Kalombo, Lonji; Nkuna, Patric; Dube, Admire; Hayeshi, Rose; Ogutu, Benhards; Gibhard, Liezl; deKock, Carmen; Smith, Peter; Wiesner, Lubbe; Swai, Hulda
: Tafenoquine (TQ), a new synthetic analog of primaquine, has relatively poor bioavailability and associated toxicity in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals. A microemulsion formulation of TQ (MTQ) with sizes 20 nm improved the solubility of TQ and enhanced the oral bioavailability from 55% to 99% in healthy mice (area under the curve 0 to infinity: 11,368±1,232 and 23,842±872 min⋅µmol/L) for reference TQ and MTQ, respectively. Average parasitemia in Plasmodium berghei-infected mice was four- to tenfold lower in the MTQ-treated group. In vitro antiplasmodial activities against chloroquinesensitive and chloroquine-resistant strains of Plasmodium falciparum indicated no change in half maximal inhibitory concentration, suggesting that the microemulsion did not affect the inherent activity of TQ. In a humanized mouse model of G6PD deficiency, we observed reduction in toxicity of TQ as delivered by MTQ at low but efficacious concentrations of TQ. We hereby report an enhancement in the solubility, bioavailibility, and efficacy of TQ against blood stages of Plasmodium parasites without a corresponding increase in toxicity.
State of the art and future directions in nanomedicine for tuberculosis.
(Expert Opinion on Drug Delivery, 2013-12-01) Dube, Admire; Lemmer, Yolandy; Hayeshi, Rose; Balogun, Mohammed; Labuschagne, Philip; Swai, Hulda; Kalombo, Lonji
Introduction: Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, for lengthy periods of time, often with severe drug-induced side effects. Nanomedicines have the potential to improve treatment outcomes by providing therapies with reduced drug doses, administered less frequently, under shortened treatment durations. Areas covered: In this article, we present the pathophysiology of the disease, focusing on pulmonary TB and the characteristics of drugs used in treatment and discuss the application of nanomedicines within this scope. We also discuss new formulation approaches for TB nanomedicines and directions for future research. Expert opinion: Nanomedicines have the potential to improve TB treatment outcomes. New approaches such as nanoparticle systems able to impact the immune response of macrophages and deliver drug intracellularly, as well as the use of polymer–drug conjugates for drug delivery, are likely to play an important role in TB nanomedicines in future. However, further research is required before TB nanomedicines can be translated to the clinic.